

Robert Striker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2612267/publications.pdf>

Version: 2024-02-01

51
papers

1,809
citations

331538
21
h-index

289141
40
g-index

53
all docs

53
docs citations

53
times ranked

3376
citing authors

#	ARTICLE	IF	CITATIONS
1	Do immune inflammatory markers correlate with anal dysplasia and anal cancer risk in patients living with HIV?. International Journal of Colorectal Disease, 2022, , 1.	1.0	0
2	Engineering Selectivity for Reduced Toxicity of Bacterial Kinase Inhibitors Using Structure-Guided Medicinal Chemistry. ACS Medicinal Chemistry Letters, 2021, 12, 228-235.	1.3	3
3	Mapping the Interactions of PKNB with Small Molecule Inhibitors using Plasma Induced Modifications of Biomolecules (PLIMB). Biophysical Journal, 2021, 120, 205a-206a.	0.2	0
4	Prevalence of High-Grade Anal Dysplasia and Anal Cancer in Veterans Living With HIV and CD4/CD8 Ratio as a Marker For Increased Risk. Diseases of the Colon and Rectum, 2021, 64, 805-811.	0.7	9
5	Risk Factors and Mortality for Atypical Presentation of COVID-19 Infection in Hospitalized Patientsâ€™-Lessons From the Early Pandemic. Wisconsin Medical Journal, 2021, 120, 94-99.	0.3	0
6	Immune recovery in HIV-1 infected patients with sustained viral suppression under long-term antiretroviral therapy in Ethiopia. PLoS ONE, 2020, 15, e0240880.	1.1	10
7	CD4/CD8 Ratio as a Novel Marker for Increased Risk of High-Grade Anal Dysplasia and Anal Cancer in HIV+ Patients: A Retrospective Cohort Study. Diseases of the Colon and Rectum, 2020, 63, 1585-1592.	0.7	15
8	Role of CD4/CD8 ratio on the incidence of tuberculosis in HIV-infected patients on antiretroviral therapy followed up for more than a decade. PLoS ONE, 2020, 15, e0233049.	1.1	13
9	77. Long Term Care Facility Residents Hospitalized with COVID-19 Infection Present with Atypical Symptoms. Open Forum Infectious Diseases, 2020, 7, S169-S170.	0.4	0
10	Title is missing!. , 2020, 15, e0233049.		0
11	Title is missing!. , 2020, 15, e0233049.		0
12	Title is missing!. , 2020, 15, e0233049.		0
13	Title is missing!. , 2020, 15, e0233049.		0
14	Anal Intraepithelial Neoplasia Screening With Anal Pap Tests: Follow-up and Corresponding Histology. Journal of Surgical Research, 2019, 244, 117-121.	0.8	5
15	Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome-wide Association Studies. American Journal of Human Genetics, 2019, 105, 763-772.	2.6	169
16	In Silico Screen and Structural Analysis Identifies Bacterial Kinase Inhibitors which Act with Î²-Lactams To Inhibit Mycobacterial Growth. Molecular Pharmaceutics, 2018, 15, 5410-5426.	2.3	22
17	CW779439X and Its Pyrazolopyridazine Derivatives Inhibit the Serine/Threonine Kinase Stk1 and Act As Antibiotic Adjuvants against Î²-Lactam-Resistant <i>Staphylococcus aureus</i>. ACS Infectious Diseases, 2018, 4, 1508-1518.	1.8	27
18	A screen for kinase inhibitors identifies antimicrobial imidazopyridine aminofurazans as specific inhibitors of the Listeria monocytogenes PASTA kinase PrkA. Journal of Biological Chemistry, 2017, 292, 17037-17045.	1.6	32

#	ARTICLE	IF	CITATIONS
19	RNA-mediated TILDA for improved cell capacity and enhanced detection of multiply-spliced HIV RNA. Integrative Biology (United Kingdom), 2017, 9, 876-884.	0.6	5
20	Imbalance in the game of T cells: What can the CD4/CD8 T-cell ratio tell us about HIV and health?. PLoS Pathogens, 2017, 13, e1006624.	2.1	177
21	The <i>Listeria monocytogenes</i> PASTA Kinase PrkA and Its Substrate Yvck Are Required for Cell Wall Homeostasis, Metabolism, and Virulence. PLoS Pathogens, 2016, 12, e1006001.	2.1	60
22	Sterol Carrier Protein 2, a Critical Host Factor for Dengue Virus Infection, Alters the Cholesterol Distribution in Mosquito Aag2 Cells. Journal of Medical Entomology, 2015, 52, 1124-1134.	0.9	21
23	Comparative analysis of the human and zebrafish kinomes: focus on the development of kinase inhibitors. Trends in Cell & Molecular Biology, 2015, 10, 49-75.	0.5	2
24	Inhibitors of Peptidyl Proline Isomerases As Antivirals in Hepatitis C and Other Viruses. PLoS Pathogens, 2014, 10, e1004428.	2.1	0
25	Selective Pharmacologic Inhibition of a PASTA Kinase Increases <i>Listeria monocytogenes</i> Susceptibility to β -Lactam Antibiotics. Antimicrobial Agents and Chemotherapy, 2014, 58, 4486-4494.	1.4	52
26	Pharmacological disruption of hepatitis C NS5A protein intra- and intermolecular conformations. Journal of General Virology, 2014, 95, 363-372.	1.3	12
27	Human immunodeficiency virus testing pitfalls and clinical suspicion. American Journal of Emergency Medicine, 2014, 32, 1442.e1-1442.e2.	0.7	3
28	Phenotypic analysis of NS5A variant from liver transplant patient with increased cyclosporine susceptibility. Virology, 2013, 436, 268-273.	1.1	7
29	Mosquito Protein Kinase G Phosphorylates Flavivirus NS5 and Alters Flight Behavior in <i>Aedes aegypti</i> and <i>Anopheles gambiae</i> . Vector-Borne and Zoonotic Diseases, 2013, 13, 590-600.	0.6	21
30	Telaprevir to Boceprevir Switch Highlights Lack of Cross-Reactivity. Clinical Infectious Diseases, 2013, 56, 552-554.	2.9	6
31	West Nile virus methyltransferase domain interacts with protein kinase G. Virology Journal, 2013, 10, 242.	1.4	19
32	Subtype Specific Differences in NS5A Domain II Reveals Involvement of Proline at Position 310 in Cyclosporine Susceptibility of Hepatitis C Virus. Viruses, 2012, 4, 3303-3315.	1.5	10
33	Addition of Ceftaroline to Daptomycin after Emergence of Daptomycin-Nonsusceptible <i>Staphylococcus aureus</i> during Therapy Improves Antibacterial Activity. Antimicrobial Agents and Chemotherapy, 2012, 56, 5296-5302.	1.4	104
34	Fluorescence Resonance Energy Transfer-Based Intracellular Assay for the Conformation of Hepatitis C Virus Drug Target NS5A. Journal of Virology, 2012, 86, 8277-8286.	1.5	14
35	Analysis of Hepatitis C Virus Intrahost Diversity across the Coding Region by Ultradeep Pyrosequencing. Journal of Virology, 2012, 86, 3952-3960.	1.5	42
36	Comparison of hepatitis C virus treatment between incarcerated and community patients. Hepatology, 2012, 56, 1252-1260.	3.6	32

#	ARTICLE	IF	CITATIONS
37	Phosphorylation events during viral infections provide potential therapeutic targets. Reviews in Medical Virology, 2012, 22, 166-181.	3.9	82
38	Vitamin D and the anti-viral state. Journal of Clinical Virology, 2011, 50, 194-200.	1.6	335
39	A Thiopurine Drug Inhibits West Nile Virus Production in Cell Culture, but Not in Mice. PLoS ONE, 2011, 6, e26697.	1.1	15
40	Cyclosporine Inhibits a Direct Interaction between Cyclophilins and Hepatitis C NS5A. PLoS ONE, 2010, 5, e9815.	1.1	84
41	Protein Kinase G Phosphorylates Mosquito-Borne Flavivirus NS5. Journal of Virology, 2009, 83, 9195-9205.	1.5	36
42	The flaviviral methyltransferase is a substrate of Casein Kinase 1. Virus Research, 2009, 141, 101-104.	1.1	25
43	Phosphorylation of yellow fever virus NS5 alters methyltransferase activity. Virology, 2008, 380, 276-284.	1.1	36
44	Thiopurines inhibit bovine viral diarrhea virus production in a thiopurine methyltransferase-dependent manner. Journal of General Virology, 2008, 89, 1000-1009.	1.3	15
45	Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology, 2007, 46, 1026-1033.	3.6	105
46	Selection of an optimal RNA transfection reagent and comparison to electroporation for the delivery of viral RNA. Journal of Virological Methods, 2007, 145, 14-21.	1.0	22
47	Tailoring immunosuppressants to hepatitis C virusâ€“infected transplant patients. Transplantation Reviews, 2006, 20, 157-164.	1.2	0
48	Milkersâ€™ Nodules Complicated by Erythema Multiforme and Graftâ€“versusâ€“Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Clinical Infectious Diseases, 2005, 40, e63-e66.	2.9	16
49	EFFECT OF ANTIMETABOLITE IMMUNOSUPPRESSANTS ON FLAVIVIRIDAE, INCLUDING HEPATITIS C VIRUS. Transplantation, 2004, 77, 562-567.	0.5	49
50	Structural requirements for the glycolipid receptor of human uropathogenic Escherichia coli. Molecular Microbiology, 1995, 16, 1021-1029.	1.2	65
51	Genetic, biochemical, and structural studies of biogenesis of adhesive pili in bacteria. Methods in Enzymology, 1994, 236, 282-306.	0.4	28